1102P Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory analyses from the IMspire150 study

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 31; p. S745
Main Authors Ascierto, P.A., Robert, C., Lewis, K., Gutzmer, R., Stroyakovskiy, D., Gogas, H.J., Protsenko, S., Pereira, R.P., Eigentler, T., Rutkowski, P., Demidov, L., Manikhas, G. Moiseevich, McNally, V., Forbes, H., Shah, K., Yan, Y., McArthur, G.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.09.2020
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2020.08.1225